Loading
A phase 3 trial of Nivolumab in melanoma, run by mAbxience Research S.L., now recruiting.
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma is a phase 3 interventional study registered as NCT07221734 by mAbxience Research S.L., with 632 participants planned, started 2025-12-29 and due to reach its primary completion in 2027-04. Interventions recorded: MB11 (Proposed Nivolumab Biosimilar), EU-Opdivo® and US- sourced Opdivo®.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Nivolumab, Melanoma and the tag pipeline.
Shares Nivolumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma and the tag pipeline.